Exhibit 5.1
140 Scott Drive | ||||
Menlo Park, California 94025 | ||||
Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com | ||||
![]() |
FIRM / AFFILIATE OFFICES | |||
Austin | Milan | |||
Beijing | Munich | |||
Boston | New York | |||
Brussels | Orange County | |||
Century City | Paris | |||
May 21, 2025 | Chicago | Riyadh | ||
Dubai | San Diego | |||
Düsseldorf | San Francisco | |||
Frankfurt | Seoul | |||
Hamburg | Silicon Valley | |||
Hong Kong | Singapore | |||
Houston | Tel Aviv | |||
London | Tokyo | |||
Los Angeles | Washington, D.C. | |||
Madrid |
Hinge Health, Inc.
455 Market Street, Suite 700
San Francisco, California 94105
Re: | Registration Statement on Form S-8 |
To the addressee set forth above:
We have acted as counsel to Hinge Health, Inc., a Delaware corporation (the Company), in connection with the preparation and filing by the Company on the date hereof with the Securities and Exchange Commission (the Commission) of a Registration Statement (the Registration Statement) on Form S-8 under the Securities Act of 1933, as amended (the Act), relating to the issuance of (i) up to 46,137,854 shares of Class A common stock of the Company, $0.00001 par value per share (the Class A Shares), and (ii) up to 13,384,433 shares of Class B common stock of the Company, $0.00001 par value per share (the Class B Shares and, together with the Class A Shares, the Shares), which may be issued pursuant to the Companys 2017 Equity Incentive Plan (the 2017 Plan), the Companys 2025 Incentive Award Plan (the 2025 Plan), and the Companys 2025 Employee Stock Purchase Plan (the ESPP and, together with the 2017 Plan and the 2025 Plan, the Plans). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related prospectus, other than as expressly stated herein with respect to the issue of the Shares.
As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the DGCL), and we express no opinion with respect to any other laws.
May 21, 2025
Page 2
Subject to the foregoing and the other matters set forth herein, it is our opinion that as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company for legal consideration of not less than par value in the circumstances contemplated by the applicable Plan, assuming in each case that the individual issuances, grants or awards under the applicable Plan are duly authorized by all necessary corporate action and duly issued, granted or awarded and exercised in accordance with the requirements of law and the applicable Plan (and the agreements duly adopted thereunder and in accordance therewith), the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and such Shares will be validly issued, fully paid and non-assessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.
This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.
Sincerely, |
/s/ Latham & Watkins LLP |